Skip to Primary Navigation

Skip to main content

Pharma speaker bureau alleged to cross into FCA territory, settles for $13.6m

A photo of a busy restaurant with brick walls and many lights
Meals at expensive restaurants are said to have been used as inducements. Photo by Daniel Zuchnik/Getty Images for NYCWFF

Kevin Kinsella

1 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

The agreement resolves allegations into whether the company’s speaker programs and meals for physicians violated anti-kickback laws.

Takeda Pharmaceuticals USA has agreed to pay $13.6m to resolve federal allegations that it violated the Anti‑Kickback Statute (AKS) by providing improper payments and benefits – such as lavish meals – to healthcare providers to encourage prescriptions of its antidepressant Trintellix, according to the US Department of Justice (DOJ).

Takeda is

, , , , , , , ,